Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s share price dropped 5.8% on Tuesday after Truist Financial lowered their price target on the stock from $25.00 to $15.00. Truist ...

Iovance Biotherapeutics, Inc. sees mixed TIL therapy success with Amtagvi in PD-1-refractory melanoma. Click here to find out ...

Iovance Biotherapeutics, Inc. IOVA incurred a fourth-quarter 2024 loss of 26 cents per share, narrower than the Zacks ...

Iovance Biotherapeutics (NasdaqGM:IOVA) recently reaffirmed its earnings guidance for 2025 and projected significant revenue growth for 2026, alongside announcing a notable revenue increase in its ...

Chardan lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $30 from $34 and keeps a Buy rating on the ...

Iovance Biotherapeutics, Inc.’s IOVA share price has dipped by 19.49%, which has investors questioning if this is right time ...

The market expects Iovance Biotherapeutics (IOVA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), with a ...

Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Iovance Biotherapeutics in a report issued ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...